Hepatitis associated anti-tuberculous treatment(HATT) has been a main obstacle in managing patients co-infected with Mycobacterium tuberculosis and hepatitis B virus(HBV). Therefore, we evaluated the factors relat...Hepatitis associated anti-tuberculous treatment(HATT) has been a main obstacle in managing patients co-infected with Mycobacterium tuberculosis and hepatitis B virus(HBV). Therefore, we evaluated the factors related to the severity of adverse effects during HATT, especially those associated with liver failure. A retrospective study was carried out at Tongji Hospital from 2007 to 2012. Increases in serum transaminase levels of 〉3, 5, and 10 times the upper limit of normal(ULN) were used to define liver damage as mild, moderate, and severe, respectively. Patients with elevated total bilirubin(TBil) levels that were more than 10 times the ULN(〉171 μmol/L) with or without decreased(〈40%) prothrombin activity(PTA) were diagnosed with liver failure. A cohort of 87 patients was analyzed. The incidence of liver damage and liver failure was 59.8%(n=52) and 25.3%(n=22), respectively. The following variables were correlated with the severity of hepatotoxicity: albumin(ALB) levels, PTA, platelet counts(PLT), and the use of antiretroviral therapies(P〈0.05). Hypo-proteinemia and antiretroviral therapy were significantly associated with liver failure, and high viral loads were a significant risk factor with an odds ratio(OR) of 2.066. Judicious follow-up of clinical conditions, liver function tests, and coagulation function, especially in patients with high HBV loads and hypoalbuminemia is recommended. It may be advisable to reconsider the use of antiviral drugs failure during the course of anti-tuberculous treatment of HBV infection patients to avoid the occurrence of furious liver failure.展开更多
目的探讨乙肝病毒(Hepatitis B Virus,HBV)感染患者血清中乙型肝炎病毒脱氧核苷酸(HBV-DNA)载量与乙肝五项指标的相关性。方法选取沛县人民医院于2022年1月—2023年1月收治的100例HBV感染患者作为研究对象,所有患者均接受HBV-DNA载量与...目的探讨乙肝病毒(Hepatitis B Virus,HBV)感染患者血清中乙型肝炎病毒脱氧核苷酸(HBV-DNA)载量与乙肝五项指标的相关性。方法选取沛县人民医院于2022年1月—2023年1月收治的100例HBV感染患者作为研究对象,所有患者均接受HBV-DNA载量与乙肝五项指标检测,并按照其HBV-DNA载量进行分组,分别为<50 IU/mL组69例、50~<10^(4) IU/mL组10例、10^(4)~10^(10) IU/mL组21例,对比3组检测结果。结果10^(4)~10^(10) IU/mL组乙型肝炎e抗体(Hepatitis B Virus e Antibody,HBeAb)、乙型肝炎e抗原(Hepatitis B e Antigen,HBeAg)、乙型肝炎表面抗原(Hapatitis B Surface Antigen,HBsAg)指标高于50~<10^(4) IU/mL组、<50 IU/mL组,50~<10^(4) IU/mL组各指标水平高于<50 IU/mL组,差异有统计学意义(P均<0.05)。相关性分析后显示,HBeAb、HBeAg、HBsAg与HBV-DNA载量呈正相关(r=0.512、0.549、0.673,P均<0.05)。结论HBV-DNA载量与HBeAb、HBeAg、HBsAg指标之间有正性关联,可为评估HBV感染程度提供一定参考依据。展开更多
基金supported in part by the Organization Department of the Central Committee of the Communist Party of China 2015“sunshine of the west”visiting scholar program(No.2903)
文摘Hepatitis associated anti-tuberculous treatment(HATT) has been a main obstacle in managing patients co-infected with Mycobacterium tuberculosis and hepatitis B virus(HBV). Therefore, we evaluated the factors related to the severity of adverse effects during HATT, especially those associated with liver failure. A retrospective study was carried out at Tongji Hospital from 2007 to 2012. Increases in serum transaminase levels of 〉3, 5, and 10 times the upper limit of normal(ULN) were used to define liver damage as mild, moderate, and severe, respectively. Patients with elevated total bilirubin(TBil) levels that were more than 10 times the ULN(〉171 μmol/L) with or without decreased(〈40%) prothrombin activity(PTA) were diagnosed with liver failure. A cohort of 87 patients was analyzed. The incidence of liver damage and liver failure was 59.8%(n=52) and 25.3%(n=22), respectively. The following variables were correlated with the severity of hepatotoxicity: albumin(ALB) levels, PTA, platelet counts(PLT), and the use of antiretroviral therapies(P〈0.05). Hypo-proteinemia and antiretroviral therapy were significantly associated with liver failure, and high viral loads were a significant risk factor with an odds ratio(OR) of 2.066. Judicious follow-up of clinical conditions, liver function tests, and coagulation function, especially in patients with high HBV loads and hypoalbuminemia is recommended. It may be advisable to reconsider the use of antiviral drugs failure during the course of anti-tuberculous treatment of HBV infection patients to avoid the occurrence of furious liver failure.
文摘目的探讨乙肝病毒(Hepatitis B Virus,HBV)感染患者血清中乙型肝炎病毒脱氧核苷酸(HBV-DNA)载量与乙肝五项指标的相关性。方法选取沛县人民医院于2022年1月—2023年1月收治的100例HBV感染患者作为研究对象,所有患者均接受HBV-DNA载量与乙肝五项指标检测,并按照其HBV-DNA载量进行分组,分别为<50 IU/mL组69例、50~<10^(4) IU/mL组10例、10^(4)~10^(10) IU/mL组21例,对比3组检测结果。结果10^(4)~10^(10) IU/mL组乙型肝炎e抗体(Hepatitis B Virus e Antibody,HBeAb)、乙型肝炎e抗原(Hepatitis B e Antigen,HBeAg)、乙型肝炎表面抗原(Hapatitis B Surface Antigen,HBsAg)指标高于50~<10^(4) IU/mL组、<50 IU/mL组,50~<10^(4) IU/mL组各指标水平高于<50 IU/mL组,差异有统计学意义(P均<0.05)。相关性分析后显示,HBeAb、HBeAg、HBsAg与HBV-DNA载量呈正相关(r=0.512、0.549、0.673,P均<0.05)。结论HBV-DNA载量与HBeAb、HBeAg、HBsAg指标之间有正性关联,可为评估HBV感染程度提供一定参考依据。